Jiangsu Apon Medical Technology Co Ltd Class A (300753) — Working Capital to Net Assets Ratio
Jiangsu Apon Medical Technology Co Ltd Class A (300753) has a Working Capital to Net Assets ratio of 41.4% as of September 2025. Working capital of CN¥283.71 Million (current assets of CN¥410.77 Million minus current liabilities of CN¥127.06 Million) is measured against net assets of CN¥686.08 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how many days can Jiangsu Apon Medical Technology Co Ltd C fund operations to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jiangsu Apon Medical Technology Co Ltd Class A Working Capital to Net Assets (2014–2024)
This chart shows how Jiangsu Apon Medical Technology Co Ltd Class A's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 41.4%, reflecting working capital of CN¥283.71 Million against net assets of CN¥686.08 Million CNY. For the complete balance sheet picture, see 300753 total assets.
Annual Working Capital to Net Assets for Jiangsu Apon Medical Technology Co Ltd Class A (2014–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangsu Apon Medical Technology Co Ltd Class A from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Jiangsu Apon Medical Technology Co Ltd C liquid asset ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 47.0% | CN¥332.82 Million | CN¥707.86 Million | CN¥458.44 Million | CN¥125.62 Million | ▲ +2.2 pp |
| 2023 | 44.8% | CN¥312.43 Million | CN¥697.20 Million | CN¥442.30 Million | CN¥129.87 Million | ▲ +1.4 pp |
| 2022 | 43.5% | CN¥298.26 Million | CN¥686.36 Million | CN¥445.38 Million | CN¥147.12 Million | ▼ -8.8 pp |
| 2021 | 52.2% | CN¥407.65 Million | CN¥780.52 Million | CN¥484.21 Million | CN¥76.56 Million | ▼ -7.0 pp |
| 2020 | 59.2% | CN¥438.06 Million | CN¥739.84 Million | CN¥523.30 Million | CN¥85.24 Million | ▼ -8.8 pp |
| 2019 | 68.0% | CN¥459.21 Million | CN¥674.88 Million | CN¥539.48 Million | CN¥80.27 Million | ▼ -4.7 pp |
| 2018 | 72.7% | CN¥445.95 Million | CN¥613.39 Million | CN¥517.88 Million | CN¥71.94 Million | ▲ +7.8 pp |
| 2017 | 64.9% | CN¥181.29 Million | CN¥279.38 Million | CN¥234.44 Million | CN¥53.15 Million | ▲ +5.6 pp |
| 2016 | 59.3% | CN¥136.21 Million | CN¥229.59 Million | CN¥201.13 Million | CN¥64.92 Million | ▼ -4.7 pp |
| 2015 | 64.1% | CN¥93.15 Million | CN¥145.40 Million | CN¥128.03 Million | CN¥34.88 Million | ▲ +6.3 pp |
| 2014 | 57.8% | CN¥47.02 Million | CN¥81.37 Million | CN¥81.45 Million | CN¥34.43 Million | — |